Sandoz’ Goldschmidt is lined up as Stada chief

  
Generate a summary of this article
Listen to this article
Beta

Peter Goldschmidt, president of Sandoz’ US subsidiary and head of the North America region, will succeed Claudio Albrecht as chief executive officer (CEO) of Stada from 1 September 2018, the German firm has announced. “Goldschmidt will build on the successful course of renewal and growth at Stada which Claudio Albrecht will continue pursuing until the transition of the CEO role,” the company stated, adding that “as previously announced, Albrecht will then move on to a non-executive position within the group”.

Peter Goldschmidt, president of Sandoz’ US subsidiary and head of the North America region, will succeed Claudio Albrecht as chief executive officer (CEO) of Stada from 1 September 2018, the German firm has announced. “Goldschmidt will build on the successful course of renewal and growth at Stada which Claudio Albrecht will continue pursuing until the transition of the CEO role,” the company stated, adding that “as previously announced, Albrecht will then move on to a non-executive position within the group”.

Confirming Goldschmidt’s departure after a 28-year career with parent company Novartis, Sandoz said he would leave the firm on 31...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Archive

ADHD Medications and Cardiovascular Effects: New Data Revealed. (A Comprehensive Evaluation of Emerging Clinical and Epidemiological Evidence on the Cardiovascular Effects Associated with Prescribed Medications for Attention Deficit Hyperactivity Disorder) - Clone - Clone

 
• By Nabil

A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.

Testing-Rising

 
• By Saba Afreen

Testing-Rising xxxx

bhvyuguig

lnkbkb

test 1

test 1

More from Generics Bulletin

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C10

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C9

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C8

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.